ABT Earnings Date: Jan 28, 2027 (Estimated) — Abbott Laboratories
NYSE · Healthcare · Medical Devices
Updated
When is ABT's next earnings date?
Abbott Laboratories (ABT) is expected to report Q4 2026 earnings on Thursday, January 28, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.64 on revenue of $13.52B.
How did ABT do in its last earnings report?
In its most recent report on Oct 21, 2026 (Q3 2026), Abbott Laboratories posted EPS of $1.42 versus the $1.42 estimate, an in-line result. Revenue was $13.01B against a $12.99B estimate. The stock's 1-day post-earnings move was -1.9%.
How much does ABT stock move after earnings?
ABT beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.4% (up or down) in the day after earnings.
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
🤖 AI Earnings Analysis
Abbott’s planned Nutrition spin-off is a material portfolio catalyst, while Q3 adjusted EPS of $1.42 matched estimates and revenue rose 14.5% reported (7.0% comparable). Results are solid, but reaffirmed $5.45–$5.60 EPS guidance offers no fresh upside signal.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-21 | Q3 2026 | 1.42 | 1.42 | +0.00% | $13.01B | ➖ Inline | -1.89% | +0.63% | — |
| 2026-07-16 | Q2 2026 | 1.28 | 1.31 | +2.34% | $12.59B | ✅ Beat | +10.72% | +12.66% | +24.65% |
| 2026-04-16 | Q1 2026 | 1.14 | 1.15 | +0.88% | $11.16B | ✅ Beat | -6.00% | -9.71% | -16.40% |
| 2026-01-22 | Q4 2025 | 1.50 | 1.50 | +0.00% | $11.46B | ➖ Inline | -10.04% | -12.16% | -7.06% |
| 2025-10-15 | Q3 2025 | 1.30 | 1.30 | +0.00% | $11.37B | ➖ Inline | -2.43% | -3.88% | -2.91% |
| 2025-07-17 | Q2 2025 | 1.25 | 1.26 | +0.80% | $11.14B | ✅ Beat | -8.52% | -4.48% | -1.86% |
| 2025-04-16 | Q1 2025 | 1.07 | 1.09 | +1.87% | $10.36B | ✅ Beat | +2.75% | +2.87% | +5.64% |
| 2025-01-22 | Q4 2024 | 1.34 | 1.34 | +0.00% | $10.97B | ➖ Inline | +0.85% | +9.07% | +14.02% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $12.59B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Medical Devices | 46.5% | $5.85B | +9.0% | $5.05B | $4.89B | $5.37B | $5.45B |
| Diagnostic Products | 24.6% | $3.09B | -47.6% | $2.52B | $2.05B | $5.90B | $6.00B |
| Nutritional Products | 17.0% | $2.14B | -3.1% | $2.13B | $2.15B | $2.21B | $2.15B |
| Established Pharmaceutical Products | 11.9% | $1.50B | +8.4% | $1.27B | $1.26B | $1.38B | $1.51B |
| Other | 0.0% | $5.0M | — | — | — | — | — |
By region
Q2 FY26 · $12.59B total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Non-US | 58.6% | $7.38B | +7.4% | $6.63B | $6.19B | $6.87B | $7.07B |
| UNITED STATES | 41.4% | $5.22B | +22.0% | $4.34B | $4.17B | $4.28B | $4.30B |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.